Aesthetic medicine of the new generation

M1 Akademie

In-house training and development is a key element of the M1 Group's business model. That is why M1 operates the M1 Akademie. The main topics of the training courses provided are new treatment procedures, innovations and product presentations in the fields of aesthetic medicine as well as plastic and aesthetic surgery. Due to this uniform training and further education of all doctors and medical staff, M1 is able to offer customers the highest quality regardless of location.

M1 Akademie at a glance:

  • Worldwide private training centre for physicians, specialists and dentists
  • Neueste Behandlungsverfahren, Innovationen und
  • Latest treatment procedures, innovations and product presentations for the areas:
    • Aesthetic medicine
    • Plastic and aesthetic surgery
  • Providing practical experience, different techniques and detailed complication management
  • Brain pool with many years of know-how
  • Represented in Germany, Austria, Switzerland, the Netherlands, UK, Croatia, Hungary and Australia

We provide quality, techniques and expertise to doctors

More about M1 Akademie

Latest news

| Investor News

Beauty segment: growth and profitability increased again

  • Revenue: +11.0% to EUR 56.9 million (H1 2025: EUR 51.2 million)
  • EBIT: +23.8% to EUR 18.6 million (H1 2025: EUR 15.0 million)
  • EBIT margin: 32.7% (H1 2025: 29.4%)

Key Group figures:

  • Group revenue: EUR 76.6 million (H1 2025: EUR 183.5 million)
  • EBITDA: EUR 17.7 million (H1 2025: EUR 20.5 million)
  • EBIT: EUR 15.6 million (H1 2025: EUR 18.0 million)
  • EBIT margin: 20.4% (H1 2025: 9.8%)
  • EBT: EUR 16.0 million (H1 2025: EUR 16.9 million)
  • Earnings per share: EUR 0.52 (H1 2025: EUR 0.63)

Beauty segment: profitability again significantly increased

  • Revenue: +5.7% to EUR 27.1 million (Q1 2025: EUR 25.6 million)
  • EBIT: +37.6% to EUR 9.2 million (Q1 2025: EUR 6.7 million)
  • EBIT margin: 33.9% (Q1 2025: 26.0%)

Group figures: shaped by the sale of HAEMATO Pharm GmbH

  • Group revenue: EUR 46.8 million (Q1 2025: EUR 92.7 million)
  • EBIT: EUR 5.0 million (Q1 2025: EUR 8.8 million)

| Investor News

M1 Kliniken AG (ISIN DE000A0STSQ8) has cancelled the treasury shares acquired under its share buyback programme and reduced its share capital accordingly.

On 25 March 2026, the Management Board resolved, with the approval of the Supervisory Board granted on 26 March 2026 and on the basis of the authorisation by the Annual General Meeting of 17 July 2024, to reduce the Company's share capital by EUR 1,088,289 from EUR 19,643,403 to EUR 18,555,114. The capital reduction became effective upon registration in the commercial register of the Local Court of Charlottenburg (HRB 107637 B) on 26 May 2026.

| Investor News

Group key figures at a glance

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)